Prognostic value of c-Met in colorectal cancer: A meta-analysis

World Journal of Gastroenterology

Volumn 21, Issue 12, 2015, Pages 3706-3710

  Liu, Yan ^a   Yu, Xiao Feng ^a   Zou, Jian ^a   Luo, Zi Hua ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

C Met; Colorectal cancer; Meta analysis; Overall survival; Prognosis

Indexed keywords

SCATTER FACTOR RECEPTOR; MET PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; HUMAN; META ANALYSIS; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; SYSTEMATIC REVIEW; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; ENZYMOLOGY; METABOLISM; MORTALITY; ODDS RATIO; PATHOLOGY; RISK FACTOR; SIGNAL TRANSDUCTION; TIME FACTOR; UPREGULATION;

BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; HUMANS; ODDS RATIO; PROTO-ONCOGENE PROTEINS C-MET; RISK FACTORS; SIGNAL TRANSDUCTION; TIME FACTORS; UP-REGULATION;

EID: 84926361705     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i12.3706     Document Type: Article

References (24)

1. Feezor RJ, Copeland EM, Hochwald SN. Significance of micrometastases in colorectal cancer. Ann Surg Oncol 2002; 9: 944-953 [PMID: 12464585]
2. Itzkowitz SH, Bloom EJ, Kokal WA, Modin G, Hakomori S, Kim YS. Sialosyl-Tn. A novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer 1990; 66: 1960-1966 [PMID: 2224793]
3. Miyahara M, Saito T, Kaketani K, Sato K, Kuwahara A, Shimoda K, Kobayashi M. Clinical significance of ras p21 overexpression for patients with an advanced colorectal cancer. Dis Colon Rectum 1991; 34: 1097-1102 [PMID: 1959459]
4. Leahy DT, Mulcahy HE, O'Donoghue DP, Parfrey NA. bcl-2 protein expression is associated with better prognosis in colorectal cancer. Histopathology 1999; 35: 360-367 [PMID: 10564391 DOI: 10.1046/j.1365-2559.1999.00743.x]
5. Zeng Z, Weiser MR, D'Alessio M, Grace A, Shia J, Paty PB. Immunoblot analysis of c-Met expression in human colorectal cancer: overexpression is associated with advanced stage cancer. Clin Exp Metastasis 2004; 21: 409-417 [PMID: 15672865]
6. Fujita S, Sugano K. Expression of c-met proto-oncogene in primary colorectal cancer and liver metastases. Jpn J Clin Oncol 1997; 27: 378-383 [PMID: 9437998 DOI: 10.1093/jjco/27.6.378]
7. Shoji H, Yamada Y, Taniguchi H, Nagashima K, Okita N, Takashima A, Honma Y, Iwasa S, Kato K, Hamaguchi T, Shimada Y. Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection. Cancer Sci 2014; 105: 1002-1007 [PMID: 24863535 DOI: 10.1111/cas.12453]
8. Yi S, Tsao MS. Activation of hepatocyte growth factor-met autocrine loop enhances tumorigenicity in a human lung adenocarcinoma cell line. Neoplasia 2000; 2: 226-234 [PMID: 10935508]
9. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17: 2815-2834 [PMID: 9921604 DOI: 10.1002/(SICI)1097-0258]
10. Kishiki T, Ohnishi H, Masaki T, Ohtsuka K, Ohkura Y, Furuse J, Watanabe T, Sugiyama M. Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS. Cancer Chemother Pharmacol 2014; 73: 749-757 [PMID: 24500024 DOI: 10.1007/s00280-014-2401-4]
11. Voutsina A, Tzardi M, Kalikaki A, Zafeiriou Z, Papadimitraki E, Papadakis M, Mavroudis D, Georgoulias V. Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer. Mod Pathol 2013; 26: 302-313 [PMID: 22936063 DOI: 10.1038/modpathol]
12. Garouniatis A, Zizi-Sermpetzoglou A, Rizos S, Kostakis A, Nikiteas N, Papavassiliou AG. FAK, CD44v6, c-Met and EGFR in colorectal cancer parameters: tumour progression, metastasis, patient survival and receptor crosstalk. Int J Colorectal Dis 2013; 28: 9-18 [PMID: 22733437 DOI: 10.1007/s00384-012-1520-9]
13. Inno A, Di Salvatore M, Cenci T, Martini M, Orlandi A, Strippoli A, Ferrara AM, Bagalà C, Cassano A, Larocca LM, Barone C. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? Clin Colorectal Cancer 2011; 10: 325-332 [PMID: 21729677 DOI: 10.1016/j.clcc.2011.03.028]
14. De Oliveira AT, Matos D, Logullo AF, DA Silva SR, Neto RA, Filho AL, Saad SS. MET Is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality. Anticancer Res 2009; 29: 4807-4811 [PMID: 20032439]
15. Lee CT, Chow NH, Su PF, Lin SC, Lin PC, Lee JC. The prognostic significance of RON and MET receptor coexpression in patients with colorectal cancer. Dis Colon Rectum 2008; 51: 1268-1274 [PMID: 18536971 DOI: 10.1007/s10350-008-9297-1]
16. Ginty F, Adak S, Can A, Gerdes M, Larsen M, Cline H, Filkins R, Pang Z, Li Q, Montalto MC. The relative distribution of membranous and cytoplasmic met is a prognostic indicator in stage I and II colon cancer. Clin Cancer Res 2008; 14: 3814-3822 [PMID: 18559601 DOI: 10.1158/1078-0432.CCR-08-0180]
17. Zeng ZS, Weiser MR, Kuntz E, Chen CT, Khan SA, Forslund A, Nash GM, Gimbel M, Yamaguchi Y, Culliford AT, D'Alessio M, Barany F, Paty PB. c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. Cancer Lett 2008; 265 : 258-269 [PMID: 18395971 DOI: 10.1016/j.canlet.2008.02.049]
18. Kammula US, Kuntz EJ, Francone TD, Zeng Z, Shia J, Landmann RG, Paty PB, Weiser MR. Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett 2007; 248: 219-228 [PMID: 16945480 DOI: 10.1016/j.canlet.2006.07.007]
19. Resnick MB, Routhier J, Konkin T, Sabo E, Pricolo VE. Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. Clin Cancer Res 2004; 10: 3069-3075 [PMID: 15131045 DOI: 10.1158/1078-0432.CCR-03-0462]
20. Umeki K, Shiota G, Kawasaki H. Clinical significance of c-met oncogene alterations in human colorectal cancer. Oncology 1999; 56: 314-321 [PMID: 10343196 DOI: 10.1159/000011985]
21. Kong-Beltran M, Stamos J, Wickramasinghe D. The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell 2004; 6: 75-84 [PMID: 15261143]
22. Kim SJ, Johnson M, Koterba K, Herynk MH, Uehara H, Gallick GE. Reduced c-Met expression by an adenovirus expressing a c-Met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumor cells in an orthotopic nude mouse model. Clin Cancer Res 2003; 9: 5161-5170 [PMID: 14613995]
23. Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H, Kim WJ, Okimoto RA, Bell DW, Sgroi DC, Christensen JG, Settleman J, Haber DA. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci USA 2006; 103: 2316-2321 [PMID: 16461907 DOI: 10.1073/pnas.0508776103]
24. Mazzone M, Comoglio PM. The Met pathway: master switch and drug target in cancer progression. FASEB J 2006; 20: 1611-1621 [PMID: 16873884 DOI: 10.1096/fj.06-5947rev]